CTAG1B and HLA-DRB1 |
cancer/testis antigen 1B |
major histocompatibility complex, class II, DR beta 1 |
|
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
|
|
|
|
CTBP1 and TCF7L2 |
C-terminal binding protein 1 |
transcription factor 7-like 2 (T-cell specific, HMG-box) |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- Degradation of beta-catenin by the destruction complex
- S37 mutants of beta-catenin aren't phosphorylated
- S33 mutants of beta-catenin aren't phosphorylated
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- XAV939 inhibits tankyrase, stabilizing AXIN
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- deletions in the AMER1 gene destabilize the destruction complex
- TCF dependent signaling in response to WNT
- AMER1 mutants destabilize the destruction complex
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- S37 mutants of beta-catenin aren't phosphorylated
- Peptide hormone metabolism
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Incretin synthesis, secretion, and inactivation
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
|
|
|
|
|
CTLA4 and LYN |
cytotoxic T-lymphocyte-associated protein 4 |
LYN proto-oncogene, Src family tyrosine kinase |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Signaling by the B Cell Receptor (BCR)
- Platelet Adhesion to exposed collagen
- Axon guidance
- Costimulation by the CD28 family
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- Regulation of KIT signaling
- FCERI mediated NF-kB activation
- EPH-ephrin mediated repulsion of cells
- Regulation of signaling by CBL
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- CD28 co-stimulation
- CTLA4 inhibitory signaling
- Cytokine Signaling in Immune system
- Role of LAT2/NTAL/LAB on calcium mobilization
- Cell surface interactions at the vascular wall
- PECAM1 interactions
- Signaling by Interleukins
- Fc epsilon receptor (FCERI) signaling
- GPVI-mediated activation cascade
- FCERI mediated Ca+2 mobilization
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- Growth hormone receptor signaling
|
|
|
|
|
CTLA4 and JAK2 |
cytotoxic T-lymphocyte-associated protein 4 |
Janus kinase 2 |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Prolactin receptor signaling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- RMTs methylate histone arginines
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Nuclear signaling by ERBB4
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- G-protein beta:gamma signalling
- Chromatin organization
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Factors involved in megakaryocyte development and platelet production
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Chromatin modifying enzymes
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
|
|
|
|
CTLA4 and FYN |
cytotoxic T-lymphocyte-associated protein 4 |
FYN proto-oncogene, Src family tyrosine kinase |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Signaling by EGFRvIII in Cancer
- Nef and signal transduction
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Host Interactions of HIV factors
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Sema3A PAK dependent Axon repulsion
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- Platelet Adhesion to exposed collagen
- Axon guidance
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- HIV Infection
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- Netrin-1 signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- CTLA4 inhibitory signaling
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- PECAM1 interactions
- CD28 dependent Vav1 pathway
- Signaling by FGFR
- Cell surface interactions at the vascular wall
- GPVI-mediated activation cascade
|
|
- Dasatinib
- 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
|
|
|
CTLA4 and AP1M1 |
cytotoxic T-lymphocyte-associated protein 4 |
adaptor-related protein complex 1, mu 1 subunit |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- HIV Infection
- Host Interactions of HIV factors
- Golgi Associated Vesicle Biogenesis
- The role of Nef in HIV-1 replication and disease pathogenesis
- Nef mediated downregulation of MHC class I complex cell surface expression
- Clathrin derived vesicle budding
- Lysosome Vesicle Biogenesis
- MHC class II antigen presentation
- trans-Golgi Network Vesicle Budding
- Adaptive Immune System
|
|
|
|
|
CTLA4 and PIK3R1 |
cytotoxic T-lymphocyte-associated protein 4 |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- GP1b-IX-V activation signalling
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
|
- Isoproterenol
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
|
|
|
CTLA4 and STAT5A |
cytotoxic T-lymphocyte-associated protein 4 |
signal transducer and activator of transcription 5A |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Signaling by PDGF
- Signaling by FGFR in disease
- Cytokine Signaling in Immune system
- Signaling by ERBB4
- Signaling by SCF-KIT
- Signaling by Interleukins
- Nuclear signaling by ERBB4
- Downstream signal transduction
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Signaling by FGFR mutants
- Interleukin-2 signaling
- Prolactin receptor signaling
- Signaling by FGFR1 fusion mutants
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Growth hormone receptor signaling
|
|
|
|
|
CTLA4 and STAT5B |
cytotoxic T-lymphocyte-associated protein 4 |
signal transducer and activator of transcription 5B |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Signaling by PDGF
- Signaling by FGFR in disease
- Cytokine Signaling in Immune system
- Signaling by ERBB4
- Signaling by SCF-KIT
- Signaling by Interleukins
- Nuclear signaling by ERBB4
- Downstream signal transduction
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Signaling by FGFR mutants
- Interleukin-2 signaling
- Prolactin receptor signaling
- Signaling by FGFR1 fusion mutants
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Growth hormone receptor signaling
|
|
|
|
|
CTLA4 and LCK |
cytotoxic T-lymphocyte-associated protein 4 |
LCK proto-oncogene, Src family tyrosine kinase |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Nef and signal transduction
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- CD28 co-stimulation
- Host Interactions of HIV factors
- CD28 dependent PI3K/Akt signaling
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- TCR signaling
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Downstream TCR signaling
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- HIV Infection
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Nef Mediated CD4 Down-regulation
- Innate Immune System
- Signalling by NGF
- Generation of second messenger molecules
- Translocation of ZAP-70 to Immunological synapse
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- CTLA4 inhibitory signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- CD28 dependent Vav1 pathway
- PECAM1 interactions
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- PD-1 signaling
- GPVI-mediated activation cascade
- Phosphorylation of CD3 and TCR zeta chains
|
|
- Dasatinib
- {4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid
- Staurosporine
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- (4-{2-Acetylamino-2-[1-(3-Carbamoyl-4-Cyclohexylmethoxy-Phenyl)-Ethylcarbamoyl}-Ethyl}-2-Phosphono-Phenoxy)-Acetic Acid
- Phosphoaminophosphonic Acid-Adenylate Ester
- 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
- 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
- N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
- Ponatinib
|
|
|
CTLA4 and TXK |
cytotoxic T-lymphocyte-associated protein 4 |
TXK tyrosine kinase |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Fc epsilon receptor (FCERI) signaling
- FCERI mediated Ca+2 mobilization
- Innate Immune System
|
|
|
|
|
CTLA4 and PPP2R5A |
cytotoxic T-lymphocyte-associated protein 4 |
protein phosphatase 2, regulatory subunit B, alpha |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Mitotic Prometaphase
- Costimulation by the CD28 family
- Separation of Sister Chromatids
- misspliced GSK3beta mutants stabilize beta-catenin
- APC truncation mutants have impaired AXIN binding
- T41 mutants of beta-catenin aren't phosphorylated
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Mitotic Anaphase
- Signaling by Wnt
- M Phase
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- Degradation of beta-catenin by the destruction complex
- S37 mutants of beta-catenin aren't phosphorylated
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- XAV939 inhibits tankyrase, stabilizing AXIN
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- CTLA4 inhibitory signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Cell Cycle, Mitotic
- Platelet homeostasis
- deletions in the AMER1 gene destabilize the destruction complex
- TCF dependent signaling in response to WNT
- Platelet sensitization by LDL
- AMER1 mutants destabilize the destruction complex
- Resolution of Sister Chromatid Cohesion
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- Mitotic Metaphase and Anaphase
- Adaptive Immune System
|
|
|
|
|
CTNNB1 and HNF1A |
catenin (cadherin-associated protein), beta 1, 88kDa |
HNF1 homeobox A |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
|
|
|
|
CTNNB1 and TCF7L2 |
catenin (cadherin-associated protein), beta 1, 88kDa |
transcription factor 7-like 2 (T-cell specific, HMG-box) |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- S37 mutants of beta-catenin aren't phosphorylated
- Peptide hormone metabolism
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Incretin synthesis, secretion, and inactivation
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
|
|
|
|
|
CTNND1 and MTNR1B |
catenin (cadherin-associated protein), delta 1 |
melatonin receptor 1B |
- Cell junction organization
- Cell-cell junction organization
- Signaling by VEGF
- Adherens junctions interactions
- VEGFR2 mediated vascular permeability
- VEGFA-VEGFR2 Pathway
|
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- GPCR downstream signaling
- Class A/1 (Rhodopsin-like receptors)
- G alpha (i) signalling events
- Metabolic disorders of biological oxidation enzymes
- GPCR ligand binding
|
|
- Ramelteon
- Melatonin
- Agomelatine
|
|
|
CTSB and INS |
cathepsin B |
insulin |
- Toll-Like Receptors Cascades
- Trafficking and processing of endosomal TLR
- Collagen formation
- Collagen degradation
- MHC class II antigen presentation
- Degradation of the extracellular matrix
- Assembly of collagen fibrils and other multimeric structures
- Adaptive Immune System
- Innate Immune System
|
- Synthesis, secretion, and deacylation of Ghrelin
- Insulin receptor signalling cascade
- Integration of energy metabolism
- Regulation of insulin secretion
- IRS-related events
- SHC-related events
- Insulin receptor recycling
- Peptide hormone metabolism
- IRS activation
- Regulation of beta-cell development
- Signal attenuation
- Regulation of gene expression in beta cells
- Insulin processing
- SHC activation
- Signaling by Insulin receptor
|
- 2-Aminoethanimidic Acid
- 3-Amino-4-Oxybenzyl-2-Butanone
- 3-Methylphenylalanine
- N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline
- 2-Pyridinethiol
- Diphenylacetic Acid
- N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE
- BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
- METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE
- N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE
|
|
|
|
CTSD and INS |
cathepsin D |
insulin |
- Peptide hormone metabolism
- Collagen degradation
- Metabolism of Angiotensinogen to Angiotensins
- MHC class II antigen presentation
- Degradation of the extracellular matrix
- Adaptive Immune System
|
- Synthesis, secretion, and deacylation of Ghrelin
- Insulin receptor signalling cascade
- Integration of energy metabolism
- Regulation of insulin secretion
- IRS-related events
- SHC-related events
- Insulin receptor recycling
- Peptide hormone metabolism
- IRS activation
- Regulation of beta-cell development
- Signal attenuation
- Regulation of gene expression in beta cells
- Insulin processing
- SHC activation
- Signaling by Insulin receptor
|
- Insulin Regular
- Insulin, porcine
- S-Methylcysteine
- Alpha-D-Mannose
- 1h-Benoximidazole-2-Carboxylic Acid
- N-Aminoethylmorpholine
- 5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOBUTYL-HEXANOIC ACID
- CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE
|
|
|
|
CTSE and INS |
cathepsin E |
insulin |
- MHC class II antigen presentation
- Adaptive Immune System
|
- Synthesis, secretion, and deacylation of Ghrelin
- Insulin receptor signalling cascade
- Integration of energy metabolism
- Regulation of insulin secretion
- IRS-related events
- SHC-related events
- Insulin receptor recycling
- Peptide hormone metabolism
- IRS activation
- Regulation of beta-cell development
- Signal attenuation
- Regulation of gene expression in beta cells
- Insulin processing
- SHC activation
- Signaling by Insulin receptor
|
|
|
|
|
CTSH and XRN1 |
cathepsin H |
5-3 exoribonuclease 1 |
- MHC class II antigen presentation
- Adaptive Immune System
|
- Regulation of mRNA stability by proteins that bind AU-rich elements
- mRNA decay by 5' to 3' exoribonuclease
- Tristetraprolin (TTP) destabilizes mRNA
- Deadenylation-dependent mRNA decay
- Butyrate Response Factor 1 (BRF1) destabilizes mRNA
|
|
|
|
|
CTSH and SFTPB |
cathepsin H |
surfactant protein B |
- MHC class II antigen presentation
- Adaptive Immune System
|
|
|
|
|
|